Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy
1 finding from 1 review
Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy
Morphine showed no clear difference in adverse eventsPercentage of participants with any adverse event compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients undergoing knee arthroscopy
3 findings from 1 review
no estimate extracted
5 studies · 248 participants
Low
no estimate extracted
6 studies · 330 participants
Low
no estimate extracted
5 studies · 270 participants
Low
Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy
1 finding from 1 review
Intervention not reported
Treatment failure · treating pulmonary TB
The intervention showed no clear difference in treatment failure (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse · treating pulmonary TB
The intervention showed no clear difference in relapse (low certainty).
1 finding from 1 review
Intervention not reported
Death · treating pulmonary TB
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum smear or culture conversion at end of treatment · treating pulmonary TB
The intervention showed no clear difference in sputum smear or culture conversion at end of treatment (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Intervention not reported
Combined endpoint of treatment failure, relapse, or death** · treating pulmonary TB
1 finding from 1 review
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 h · adults with acute postoperative pain
The intervention probably leads to higher at least 50% of maximum pain relief over 4 to 6 h (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants remedicating within 4 to 6 h · adults with acute postoperative pain
The intervention may leads to lower participants remedicating within 4 to 6 h (low certainty).
1 finding from 1 review
Intervention not reported
Participants with at least one adverse event · adults with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Participants with a serious adverse event · adults with acute postoperative pain
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review